New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma
BioMed Research International · 2025
DOI: 10.1155/bmri/5694628 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2025. Verfasst von Yonghui Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Vascular Endothelial Growth Factor A, Esophageal Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims The effects of vascular endothelial growth factor (VEGF) overexpression on the prognosis of patients with esophageal squamous cell carcinoma (ESCC) are still unclear. The aim of this study was to construct and evaluate a mutant gene–based model to predict the prognosis of ESCC patients with VEGF overexpression.
Methods
Samples from 50 ESCC patients with VEGF overexpression were subjected to next‐generation sequencing (NGS) to identify gene mutations. The associations between the enrichment of these mutations and patient outcomes were also evaluated in a cohort from The Cancer Genome Atlas. Hazard ratios were identified via the Kaplan–Meier and Cox analyses. A support vector machine recursive feature elimination algorithm was used to construct the model, and receiver operating characteristic analysis was carried out to evaluate its prognostic performance.
Results
ESCC patients with FAT1 , FGF3 , FGF12 , and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses.
Conclusion
A model based on a four‐gene signature effectively predicts the prognosis of ESCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn.
ORCID-Profile: Haibo Wang, Tingting Li
Zitieren
APA
Li, Y., Wang, R., Wang, H., Li, T., Zhang, C. L., Dong, S., & Zhang, B. (2025). New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma. BioMed Research International. https://doi.org/10.1155/bmri/5694628
Vancouver
Li Y, Wang R, Wang H, Li T, Zhang CL, Dong S, et al. New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma. BioMed Research International. 2025. doi:10.1155/bmri/5694628
BibTeX
@article{Li2025,
author = {Li, Yonghui and Wang, Ruiyao and Wang, Haibo and Li, Tingting and Zhang, Cheng Long and Dong, Shaoyong and Zhang, Biao},
title = {New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma},
journal = {BioMed Research International},
year = {2025},
doi = {10.1155/bmri/5694628}
}
EUVIMED